Clúster de Colegios y asociaciones de salud
Table A. Dosing Regimens and Comments for the Drugs Recommended in Figure 2 Drug Name Dosing Regimen Comments Remdesivir Remdesivir 200 mg IV once, then remdesivir 100 mg IV once daily for 4 days or until hospital discharge Treatment may be extended for up to 10 days if there is […]
Contribution To Literature: The MICHELLE trial showed that rivaroxaban after hospitalization for COVID-19 improved clinical outcomes without increasing bleeding. Description: The goal of the trial was to evaluate rivaroxaban compared with control among patients discharged after hospitalization for coronavirus 2019 (COVID-19) infection. Study Design Randomization Parallel Participants discharged after COVID-19 […]
Compared with placebo, this Janus kinase inhibitor was associated with lower risk for death or respiratory failure in such patients. In patients hospitalized with COVID-19, excess inflammation generally underlies clinical progression. By reducing cytokine production, Janus kinase (Jak) inhibitors tamp down inflammation. Now, investigators report results of an industry-supported trial […]
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1–3). In an evaluation at 24 hospitals in 14 states,* the […]